Article thumbnail

Lymphocyte Cell-Cycle Inhibition by HLA-G Is Mediated by Phosphatase SHP-2 and Acts on the mTOR Pathway

By Farah Ketroussi, Massimo Giuliani, Rajia Bahri, Bruno Azzarone, Bernard Charpentier and Antoine Durrbach


Human leukocyte antigen G (HLA-G) is involved in regulating T-cell responses through its interaction with inhibitory receptors belonging to the immunoglobulin-like transcript family (ILT). In this context, we investigated the pathways involved in the control of cell-cycle entry of T cells following HLA-G interaction with its inhibitory receptor. We show that HLA-G acts through its interaction with the LILRB1 receptor expressed on T lymphocytes. Both HLA-G and LILRB1 antibodies block the inhibitory effect of HLA-G and restore T-cell proliferation. The interaction of HLA-G with T lymphocytes is associated with phosphorylation of SHP-2 phosphatase, but not SHP-1. In addition, in activated T cells, their incubation with HLA-G is not associated with a decrease in the TCR or CD28 downstream pathways, but is associated with dephosphorylation of the mTOR molecule and p70S6K. In contrast, Akt, which acts upstream of mTOR, is not affected by HLA-G. The inhibition of SHP-2 by NSC-87877(5 µM), a chemical inhibitor of SHP-2, or the use of siRNA, abrogates dephosphorylation of mTOR and impairs the overexpression of p27kip in the presence of HLA-G. Together, these results indicate that HLA-G is associated with activation of phosphatase SHP-2, which inhibits the mTOR pathway and favors the inhibition of the cell-cycle entry of human-activated T cells

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1999). A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells.
  2. (1997). A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules.
  3. (2010). A novel mechanism of soluble HLA-G mediated immune modulation: downregulation of T cell chemokine receptor expression and impairment of chemotaxis.
  4. (2004). Alloreactive CD4+ and CD8+ T cells express the immunotolerant HLA-G molecule in mixed lymphocyte reactions: In vivo implications in transplanted patients.
  5. (2007). CD3+CD4low and CD3+CD8low are induced by HLA-G: novel human peripheral blood suppressor T cell subsets involved in transplant acceptance.
  6. (2001). Crystal structure of the human natural killer cell inhibitory receptor KIR2DL1-HLA-Cw4 complex.
  7. (2000). Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8.
  8. (2006). Discovery of a novel shp2 protein tyrosine phosphatase inhibitor.
  9. (2006). Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/regulatory T cells.
  10. (2003). Expression of HLA-G in human cornea, an immune-privileged tissue.
  11. (2003). HLA-G expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation.
  12. (1999). HLA-G inhibits the allogeneic proliferative response.
  13. (2000). HLA-G inhibits the transendothelial migration of human NK cells.
  14. (2000). HLA-G suppresses proliferation of CD4(+) T-lymphocytes.
  15. (1999). HLA-Gmediated inhibition of antigen-specific cytotoxic T lymphocytes.
  16. (2003). Horuzsko A
  17. (2002). Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection. Circulation 105(16): 1949–54. HLA-G Inhibits mTOR via SHP-2 PLoS
  18. (1997). Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts.
  19. (2000). Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells.
  20. (2009). Immunohistochemical study of HLA-G expression in lung transplant recipients.
  21. (2001). Liver-derived dendritic cells induce donor-specific hyporesponsiveness: use of sponge implant as a cell transplant model.
  22. (2008). Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6–STAT3 signaling pathway.
  23. (2002). Mutational analysis of immunoreceptor tyrosine-based inhibition motifs of the Ig-like transcript 2 (CD85j) leukocyte receptor.
  24. (2009). SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels.
  25. (2008). SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients.
  26. (2003). Soluble HLA-A, -B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation.
  27. (2003). Soluble HLA-G inhibits human dendritic cell-triggered allogeneic T-cell proliferation without altering dendritic differentiation and maturation processes.
  28. (2001). Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the alloproliferative response: a CD4+ T cell regulatory mechanism.
  29. (1990). Specific suppression of allograft rejection by soluble class I antigen and complexes with monoclonal antibody.
  30. (1997). Specificity and function of immunoglobulin superfamily NK cell inhibitory and stimulatory receptors.
  31. (1997). The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors?
  32. (2000). The CD85/ LIR-1/ILT2 inhibitory receptor is expressed by all human T lymphocytes and down-regulates their functions.
  33. (1999). The inhibitory receptor LIR1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18.
  34. (1998). The MHC class I binding proteins LIR-1 and LIR-2 inhibit Fc receptormediated signaling in monocytes.